U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520305) titled 'Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes' on April 03.
Brief Summary: This is a single-arm study to investigate the heterogeneity of glycemic response to Lactobacillus paracasei LC19 in patients with newly diagnosed type 2 diabetes. Participants will receive LC19 for 12 weeks, and changes in glycemic control will be evaluated.
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DIETARY_SUPPLEMENT: Lactobacillus paracasei LC19 Intervention
All participants will receive oral Lactobacillus paracasei LC19 powder (2 g/packet, 2 packets/day) for 12 weeks....